Cooperative Agreement U01CA301249
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $361K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Pennsylvania, USA
Similar Awards
- The University of Pittsburgh received a $585,931 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) on February 3, 2025. The grant will fund a comprehensive research framework to determine the molecular credentials and selection of cancer models, such as cell lines, patient-derived xenografts (PDX), and patient-derived organoids (PDO), to guide translational and clinical applications in breast cancer. The key objectives are: (1) identifying and...
- The University of Pittsburgh was awarded a $408,829 Project Grant from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to develop an "Integrative Framework for Surface Protein Imputation for Spatial Biology of Cancer". The goal of the project is to increase the utility of spatial transcriptomics datasets by imputing surface protein abundance through incorporating spatial and histological dependencies, and simultaneously learning the RNA-protein mapping relation from...
- This federal Project Grant award of $1,899,042.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research at the University of Pittsburgh to analyze high-dimensional genomic datasets to reveal mechanistic insights on divergent outcomes of head and neck cancer. The project aims to use existing public databases of human head and neck squamous cell carcinomas (HNSCC) to identify new mechanisms...
- The University of Pittsburgh received a $180,632 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on halting breast cancer metastasis. The project aims to discover and validate compounds that can block the engulfment of mesenchymal stem cells (MSCs) by breast cancer cells, as this process has been linked to increased tumor growth, metastasis, and chemotherapy resistance. Using microfluidic technology, the researchers will create a...
- The University of Pittsburgh has been awarded a $151,920 federal Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396). The goal of the research project is to design tailored NMR strategies for investigating inhibitor-induced conformational changes in the Src family kinase HCK, which is implicated in the development of acute myeloid leukemia. The research will focus on using tryptophan residues and site-specific 19F detection as sensitive probes...
- This Project Grant award of $176,712.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh, supports research on immunosurveillance mechanisms that eliminate pre-cancerous cells prior to the formation of malignancies. The primary objective is to investigate how tumor-derived heat shock proteins (HSPs) engage the CD91 receptor on antigen-presenting cells, leading to priming of T cell responses against emerging tumors. This research...
- This $520,259 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research at Carnegie Mellon University to develop a liquid biopsy-based approach for predicting pathological complete response in breast cancer patients. The project aims to leverage extracellular vesicles and advanced sequencing techniques to enable ultrasensitive detection of breast cancer-specific genetic mutations. As a...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $346,319.00 to the University of Pittsburgh to conduct research on "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER." The award period runs from August 1, 2024 to July 31, 2027. The University of Pittsburgh, a major public research university, will leverage its expertise in...
- This Project Grant award of $109,076 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to identify patterns of gene deletions in metastatic breast cancer. The award, which runs from January 21, 2026 to July 31, 2029, aims to leverage machine learning techniques and comprehensive autopsy data to create a detailed landscape of genomic evolution in late-stage metastatic disease. The research, conducted by the University of Pittsburgh, seeks to...
- This $846,182 Project Grant award to the University of Pittsburgh was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project titled "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER" with a performance period from Aug 1, 2024 to Jul 31, 2027. As a major research university, the University of Pittsburgh will leverage its extensive...